The Reduction of Inflammatory Biomarkers by Statin, Fibrate, and Combination Therapy Among Diabetic Patients With Mixed Dyslipidemia. The DIACOR (Diabetes and Combined Lipid Therapy Regimen) Study

Journal of the American College of Cardiology

Volumn 48, Issue 2, 2006, Pages 396-401

  Muhlestein, Joseph B ^a,b   May, Heidi T ^a   Jensen, Jonathan R ^a   Horne, Benjamin D ^a   Lanman, Richard B ^c   Lavasani, Farangis ^a   Wolfert, Robert L ^c   Pearson, Robert R ^a   Yannicelli, H Daniel ^d   Anderson, Jeffrey L ^a,b  

^a LDS HOSPITAL   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c diaDexus Inc   (United States)

^d ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CREATINE KINASE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; PHOSPHOLIPASE A2; PLACEBO; SIMVASTATIN; TRIACYLGLYCEROL;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DYSLIPIDEMIA; FEMALE; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; LIVER TOXICITY; MALE; MYALGIA; MYOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RHABDOMYOLYSIS; TREATMENT OUTCOME;

ANTILIPEMIC AGENTS; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; PHOSPHOLIPASES A; PROCETOFEN; SIMVASTATIN;

EID: 33745685394     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2006.05.009     Document Type: Article

References (13)

1. American Heart Association. 2004 Heart Disease and Stroke Statistical Update (2004), American Heart Association, Dallas, TX
2. Beckman J.A., Creager M.A., and Libby P. Diabetes and atherosclerosis. JAMA 287 (2002) 2570-2581
3. Ridker P.M., Rifai N., Rose L., et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347 (2002) 1557-1565
4. Ridker P.M., Cushman M., Stampfer M.J., et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently health men. N Engl J Med 336 (1997) 973-979
5. Ridker P.M., and Cook N. Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores. Circulation 109 (2004) 1955-1959
6. Albert M.A., Danielson E., Rifai N., and Ridker P.M. Effect of statin therapy on C-reactive protein levels: the Pravastatin Inflammation/CRP Evaluation (PRINCE): a randomized trial and cohort study. JAMA 286 (2001) 64-70
7. Yesilbursa D., Serdar A., Saltan Y., et al. The effect of fenofibrate on serum paraoxonase activity and inflammatory markers in patients with combined hyperlipidemia. Kardiol Pol 62 (2005) 526-530
8. Schaefer E.J., McNamara J.R., Asztalos B.F., et al. Effects of atorvastatin versus other statins on fasting and postprandial C-reactive protein and lipoprotein-associated phospholipase A2 in patients with coronary heart disease versus control subjects. Am J Cardiol 95 (2005) 1025-1032
9. Koh K.K., Quon M.J., Han S.H., et al. Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia. J Am Coll Cardiol 4 (2005) 1649-1653
10. Cortellaro M., Confrancesco E., Boscetti C., et al. Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study). Fluvastatin Alone and in Combination Treatment. Thromb Haemost 83 (2000) 549-553
11. Caslake M.J., Packard C.J., Suckling K.E., et al. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase. a potential new risk factor for coronary artery disease. Atherosclerosis 150 (2000) 413-419
12. Albert M.A., Glynn R.J., Wofert R.L., and Ridker P.M. The effect of statin therapy on lipoprotein associated phospholipase A2 levels. Atherosclerosis 182 (2005) 193-198
13. Ridker P.M., Cannon C.P., Morrow D., et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352 (2005) 20-28